Asian pharmaceutical stocks experienced a sharp decline after US President Donald Trump declared plans to reduce prescription drug prices in the United States. This announcement, made via social media, signaled an aggressive move by the Trump administration to align domestic drug prices with international benchmarks, sending shockwaves through equity markets in Japan and South Korea.

Japanese and Korean Pharma Companies See Immediate Impact

Shares of Japanese pharmaceutical giants like Chugai Pharmaceutical Co., Daiichi Sankyo Co., and Takeda Pharmaceutical Co. fell sharply, with Chugai plunging as much as 7.2%, marking its largest single-day drop in a month. Takeda and Daiichi Sankyo both declined around 5% in Tokyo trading.

In South Korea, a similar trend was observed. SK Biopharmaceuticals Co., Celltrion Inc., and Samsung Biologics Co. each fell over 3%. These losses are directly tied to fears that the profit margins of these companies could suffer if they are forced to reduce prices for drugs sold in the US, one of their most lucrative markets.

Trump’s Executive Order: A Game-Changer for Pharma Pricing

Trump stated that he would sign an executive order on Monday in Washington aimed at bringing US drug prices in line with what other countries pay. While he did not go into extensive detail, the implication is clear — pharmaceutical firms that sell heavily into the US market may need to offer steep discounts or revise their pricing structures, thereby threatening their profitability.

This executive order follows speculations and reports from the prior week that hinted at such a move, which had already begun to spook investors and analysts. The official confirmation added weight to those concerns, triggering immediate sell-offs in pharma stocks.

Analysts Flag Uncertainty and Sector Vulnerability

Despite the bold announcement, analysts have cast doubt on the feasibility and implementation of Trump’s plan. Hidemaru Yamaguchi, healthcare sector analyst at Citigroup Global Markets Japan Inc., mentioned in a note that the execution of such a policy is questionable, yet still acknowledged that the sentiment impact on the sector is undeniably negative.

According to Yamaguchi, companies most reliant on US revenues, such as Takeda Pharmaceutical, Astellas Pharma Inc., and Otsuka Holdings Co., are especially exposed. Shares of Astellas and Otsuka were also down in early trade.

Why the US Market Matters So Much

The US is often seen as a high-margin market for global drugmakers, primarily because the country allows market-based drug pricing, unlike several other nations that use regulatory bodies to cap or negotiate medicine prices. Therefore, a mandate to lower US prices could force pharma companies to revisit their global revenue models.

Additionally, many new and innovative drugs are first launched in the US, making it a key source of early returns on R&D investments. A reduction in price margins here could result in a domino effect, impacting investment into future research, drug development timelines, and overall healthcare innovation.

Market Reactions: A Cautious Outlook Ahead

The pharma sell-off also reflects the broader investor uncertainty about how and when such price cuts would be implemented. The fact that this comes from an executive order rather than legislative reform means that it could be subject to legal and political challenges, especially with elections on the horizon.

Nonetheless, market players are reacting to the headline risk. Even rumors of pricing reform have historically sent pharma stocks lower, and this confirmed push by Trump, regardless of its current practicality, has reaffirmed concerns of long-term pressure on the industry.

Regional Breakdown of Affected Companies

• Japan:

  • Chugai Pharmaceutical Co.: Dropped 7.2%

  • Daiichi Sankyo Co.: Down ~5%

  • Takeda Pharmaceutical Co.: Down ~5%

  • Astellas Pharma Inc. and Otsuka Holdings Co.: Also traded lower

• South Korea:

  • SK Biopharmaceuticals Co.: Down over 3%

  • Celltrion Inc.: Down over 3%

  • Samsung Biologics Co.: Down over 3%

These companies have strong export ties to the US, making them particularly sensitive to any regulatory changes in American drug pricing policy.

Conclusion: Global Pharma Industry on Edge

While the full impact of Trump’s executive order remains to be seen, its announcement has already caused a ripple effect in global stock markets, particularly within the pharmaceutical sector. This move, seen as a populist attempt to lower US healthcare costs, may have deep and lasting effects on global pharmaceutical pricing strategies and could reshape the industry's financial outlook if successfully implemented.

Investors are now closely watching for more details when Trump officially signs the executive order, and further statements from the White House or the Department of Health and Human Services could either calm or further agitate market sentiments.

The coming weeks will be crucial, not just for Asian pharma firms, but for the global pharmaceutical industry, which may soon have to redefine its pricing approach for the US market — one of its largest sources of revenue.

The Upcoming IPOs in this week and coming weeks are Integrity Belrise Industries, Integrity Infrabuild Developers, Accretion Pharmaceuticals, Wagons Learning.

The Current active IPO are Virtual Galaxy Infotech.

Start your Stock Market Journey and Apply in IPO by Opening Free Demat Account in Choice Broking FinX.

Join our Trading with CA Abhay Telegram Channel for regular Stock Market Trading and Investment Calls by CA Abhay Varn - SEBI Registered Research Analyst.